Pheochromocytomas Completed Phase 2 Trials for Axitinib (DB06626)

Also known as: Pheochromocytoma / Chromaffin cell neoplasm (morphologic abnormality) / Phaeochromocytoma / Pheochromocytoma (morphologic abnormality) / Phaeochromocytoma [Ambiguous]

IndicationStatusPhase
DBCOND0071316 (Pheochromocytomas)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01967576Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/ParagangliomaTreatment